Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | XIAP | P98170 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | CTSG | P08311 | 1/20 | 0.36 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4666624 | 0.79 | CYP3A4 (0.44) | GAAL3MBTL1ATMALDH1A1ELANE | |
| SCHEMBL4664750 | 0.77 | GAA (0.40) | GAAL3MBTL1ATMALDH1A1XIAP | |
| SCHEMBL8007692 | 0.74 | ALDH1A1 (0.38) | GAAL3MBTL1ALDH1A1TSHR | |
| SCHEMBL6604162 | 0.74 | ALDH1A1 (0.38) | GAAL3MBTL1ALDH1A1TSHR | |
| SCHEMBL7406895 | 0.71 | ALDH1A1 (0.40) | GAAL3MBTL1ALDH1A1HSD11B1XIAP | |
| SCHEMBL17151112 | 0.70 | GAA (0.42) | GAAL3MBTL1ATMTSHR | |
| SCHEMBL6296227 | 0.69 | GAA (0.39) | GAAL3MBTL1ALDH1A1HSD11B1BACE1 | |
| SCHEMBL6297922 | 0.69 | GAA (0.39) | GAAL3MBTL1ALDH1A1HSD11B1BACE1 | |
| SCHEMBL5795799 | 0.69 | MLNR (0.39) | GAAL3MBTL1ALDH1A1HSD11B1BACE1 | |
| SCHEMBL6702703 | 0.69 | MLNR (0.39) | GAAL3MBTL1ALDH1A1HSD11B1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | GODEL THIERRY | 2008-06-05 | — | — | US | disclosed |
| EP-1689729-A1 | TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE | F. Hoffmann-La Roche AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005058857-A1 | TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| US-20050119329-A1 | Tetronic and tetramic acids | HOFFMANN-LA ROCHE INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | BACE1, PSEN1, BACE2 | GAA 70/4885L3MBTL1 3123/4885ATM 4649/4885 |
| US-20050119329-A1 | Tetronic and tetramic acids | BACE1, PSEN1, BACE2 | GAA 70/4885L3MBTL1 3123/4885ATM 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.